Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Oct 30, 2017
Open Peer Review Period: Oct 31, 2017 - Nov 30, 2017
Date Accepted: Jan 7, 2018
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study

Hohl CM, Small SS, Peddie D, Badke K, Bailey C, Balka E

Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study

JMIR Public Health Surveill 2018;4(1):e21

DOI: 10.2196/publichealth.9282

PMID: 29487041

PMCID: 5849794

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study

  • Corinne M Hohl; 
  • Serena S Small; 
  • David Peddie; 
  • Katherin Badke; 
  • Chantelle Bailey; 
  • Ellen Balka

Background:

Adverse drug events are unintended and harmful events related to medications. Adverse drug events are important for patient care, quality improvement, drug safety research, and postmarketing surveillance, but they are vastly underreported.

Objective:

Our objectives were to identify barriers to adverse drug event documentation and factors contributing to underreporting.

Methods:

This qualitative study was conducted in 1 ambulatory center, and the emergency departments and inpatient wards of 3 acute care hospitals in British Columbia between March 2014 and December 2016. We completed workplace observations and focus groups with general practitioners, hospitalists, emergency physicians, and hospital and community pharmacists. We analyzed field notes by coding and iteratively analyzing our data to identify emerging concepts, generate thematic and event summaries, and create workflow diagrams. Clinicians validated emerging concepts by applying them to cases from their clinical practice.

Results:

We completed 238 hours of observations during which clinicians investigated 65 suspect adverse drug events. The observed events were often complex and diagnosed over time, requiring the input of multiple providers. Providers documented adverse drug events in charts to support continuity of care but never reported them to external agencies. Providers faced time constraints, and reporting would have required duplication of documentation.

Conclusions:

Existing reporting systems are not suited to capture the complex nature of adverse drug events or adapted to workflow and are simply not used by frontline clinicians. Systems that are integrated into electronic medical records, make use of existing data to avoid duplication of documentation, and generate alerts to improve safety may address the shortcomings of existing systems and generate robust adverse drug event data as a by-product of safer care.


 Citation

Please cite as:

Hohl CM, Small SS, Peddie D, Badke K, Bailey C, Balka E

Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study

JMIR Public Health Surveill 2018;4(1):e21

DOI: 10.2196/publichealth.9282

PMID: 29487041

PMCID: 5849794

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.